Stroke

The medical director of the stroke recovery program at Hackensack Meridian Health JFK Johnson Rehabilitation Institute provided clinical insights into her presentation focused on expanding rehab care for stroke survivors across settings. [WATCH TIME: 5 minutes]

Eva Mistry, MD, an associate professor of neurology at the University of Cincinnati, discusses the mechanism, rationale, and clinical data supporting SCP776, a first-in-class IGF-1-based cerebroprotective therapy for acute ischemic stroke.

Neurology News Network for the week ending November 8, 2025. [WATCH TIME: 4 minutes]

A 2025 study published in Neurology® found that people with both gum disease and dental cavities face significantly higher long-term risks of stroke and major cardiovascular events compared with those with good oral health.

New clinical trial results show LT3001's promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 31, 2025.

Andrew Russman, DO, medical director of Cleveland Clinic’s Comprehensive Stroke Center, shared insights on stroke awareness, prevention, and the growing importance of heart-brain collaboration in care.

Amid World Stroke Day, neurosurgeon Evan Luther, MD, discussed the PICASSO trial’s effort to clarify the role of acute carotid stenting during mechanical thrombectomy for tandem occlusions in ischemic stroke.

The chief science officer at the American Heart Association discusses its priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day 2025.

In this final episode, Drs. Snelling and De Los Rios share lessons from building a coordinated, multi-hospital stroke system and how network integration improves speed, access, and outcomes. [WATCH TIME: 3 minutes]

In episode 4, neurologists Brian Snelling, MD, and Felipe De Los Rios, MD, discuss how stroke recovery and secondary prevention have evolved, highlighting new therapies, combination strategies, and the complexities of real-world implementation. [WATCH TIME: 4 minutes]

The conversation centers around the pursuit of effective neuroprotective agents in stroke, the challenges of clinical trial design, and what could make future therapies succeed. [WATCH TIME: 5 minutes]

At CNS 2025, the program director of child neurology residency at Boston Children's Hospital discussed strategies to expose medical students to child neurology early in their clinical training. [WATCH TIME: 4 minutes]

In episode 2, a pair of stroke neurologists explore how artificial intelligence is accelerating stroke detection, streamlining workflows, and redefining collaboration in modern stroke care. [WATCH TIME: 4 minutes]

In this kickoff episode, Drs. Brian Snelling, MD, and Felipe De Los Rios, MD, discussed how evolving evidence continues to expand mechanical thrombectomy eligibility, from extended time windows to large-core and medium-vessel occlusions. [WATCH TIME: 6 minutes]

The codirector of interventional neuroradiology at Baptist Health's Neuroscience Institute, outlined a pragmatic, anatomy-first approach to aneurysm care, balancing endovascular options against open surgery and ways to tailor decision-making. [WATCH TIME: 3 minutes]

The co-director of interventional neuroradiology at Baptist Health Miami Neuroscience Institute discussed decision-making for ruptured and unruptured aneurysm, endovascular and open outcomes, and training priorities for modern cerebrovascular care.

Portable optical blood flow monitors can enhance prehospital stroke diagnosis, enabling faster, accurate triage for large vessel occlusions and improving patient outcomes.

Semaglutide demonstrates superior cardiovascular benefits over dulaglutide, reducing heart attack and stroke risks in type 2 diabetes patients.

Grace Therapeutics reveals promising results for GTx-104, an innovative IV treatment for aSAH, potentially transforming patient care in neurocritical settings.

A recent trial reveals perispinal etanercept is safe for chronic stroke patients but shows no significant efficacy compared with placebo.

Novo Nordisk's semaglutide gains EU approval as the first oral GLP-1 RA to reduce cardiovascular risks in type 2 diabetes patients.

A recent study reveals GLP-1 receptor agonists significantly reduce medication use and symptoms in idiopathic intracranial hypertension patients, suggesting a promising management strategy.

Semaglutide significantly reduced the risk of heart attack, stroke, and death compared to tirzepatide in patients with obesity and cardiovascular disease.

Impaired kidney function significantly increases the risk of recurrent ischemic stroke, highlighting the need for tailored treatment strategies in high-risk patients.